Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2022-08-04 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, specifically focusing on 'Notification of Major Holdings' by JPMorgan Chase & Co. It details the acquisition/disposal of shares with voting rights, providing percentages and absolute numbers of voting rights attached to shares and instruments, referencing German Securities Trading Act (WpHG) sections. This directly corresponds to the definition of a notification regarding changes in significant share ownership thresholds, which aligns best with the Major Shareholding Notification (MRQ) category. Although it mentions 'Voting Rights Announcements' in the header, MRQ is the specific regulatory filing type for reporting major holdings crossing thresholds.
2022-08-04 English
Half-yearly financial report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Half-Year Report JANUARY – JUNE' and contains comprehensive financial statements (Consolidated Statement of Profit or Loss, Balance Sheet, Cash Flows) and an 'Interim Group Management Report'. It covers the period from January to June 2022, which is a standard interim reporting period. It is not an announcement of a report (RPA) because it contains the full content of the report itself, nor is it a full annual report (10-K). Therefore, it is classified as an Interim/Quarterly Report. H2 2022
2022-08-04 German
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
Earnings Release Classification · 1% confidence The document is a 'Media Release' from MorphoSys AG detailing their financial results for the second quarter and first half of 2022. It contains key financial highlights, revenue breakdowns, operating expenses, and updated financial guidance. While it provides substantive financial data, it is structured as a press release (Earnings Release) rather than a full statutory interim report. It fits the definition of an Earnings Release (ER) as it provides the initial announcement of quarterly/periodical financial results with key highlights. Q2 2022
2022-08-03 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') by a legal entity (JPMorgan Chase & Co.) in MorphoSys AG, referencing specific sections of the German Securities Trading Act (WpHG, specifically Article 40, Section 1). This content directly corresponds to the definition of reporting changes in significant share ownership thresholds, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although it is a regulatory announcement disseminated via DGAP, the specific content is about major holdings, making MRQ more precise than the general RNS fallback.
2022-08-01 English
MorphoSys AG: Invitation to MorphoSys Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
Report Publication Announcement Classification · 1% confidence The document is an announcement titled "Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022". It explicitly states that the company will publish its results on August 3, 2022, and then invites participants to a conference call/webcast on August 4, 2022, to present those results. This structure—announcing the upcoming release of results and inviting people to the subsequent discussion/call—is characteristic of an Earnings Release (ER) or a precursor to one, but since the primary focus is the invitation to the conference call where results are discussed, it strongly aligns with the definition of a Call Transcript (CT) or an Earnings Release (ER) announcement. Given the content is an invitation to the call where the 'second quarter and first half year financial results 2022' will be presented, it is most accurately classified as an announcement related to the earnings event. Since it is an invitation to the call itself, and not the transcript or the initial release of the numbers, it functions as a precursor announcement. However, the key event being promoted is the discussion of the 'Second Quarter and First Half Year 2022 Results'. This points towards an Earnings Release (ER) context, or potentially a Call Transcript (CT) if the call itself was the main subject. Since the document is an invitation to the call, and not the transcript of the call, and it precedes the actual release of the detailed results (which are published the day before the call), it is best classified as an announcement related to the earnings event. The closest fit among the options for an announcement centered around the presentation of period results is ER, or if we consider the call itself, CT. Given the document is an invitation to the conference call where results are presented, and the key financial period is mentioned ('Second Quarter and First Half Year 2022 Results'), it is most closely related to the Earnings Release process. If the document were the transcript, it would be CT. If it were the initial press release of the numbers, it would be ER. This is an invitation to the call. In many databases, such an invitation is grouped with the ER. However, since it specifically details the conference call logistics, 'Call Transcript' (CT) is a possibility if we interpret it as the announcement *about* the call. Given the options, and the focus on the conference call presentation of results, I will classify it as related to the earnings event. Since it is an invitation to the call, and not the transcript, ER is a strong candidate as it announces the results presentation event. If the document was purely about the call logistics without mentioning the results publication date, CT might be better. Given the context of 'Half Year Results' being the key word, ER is the most appropriate classification for the event announcement.
2022-07-28 English
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Earnings Release Classification · 1% confidence The document is a press release dated July 26, 2022, titled "MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022." It provides preliminary sales figures, updates financial guidance (revenue and expenses) for the full year 2022, and mentions that full results will be published later (August 3, 2022). This content—the initial announcement of key financial highlights for a period (Q2 2022) and guidance revision—is the definition of an Earnings Release (ER). It is not the full, comprehensive report (like 10-K or IR), nor is it a transcript or a general regulatory filing fallback. Q2 2022
2022-07-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.